Evidence map›Paper›PMID 25516616›Full record

ArticlemBio2014

Sirtuins are evolutionarily conserved viral restriction factors.

Emre Koyuncu, Hanna G Budayeva, Yana V Miteva, Dante P Ricci, Thomas J Silhavy, Thomas Shenk, Ileana M Cristea

Open access · goldAbstract read
In one paragraph

Article in mBio, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers.

0numbers the graph read from it
0cells of the map it votes in
105citing papers in PubMed
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

105 citing papers in PubMed, 144 citations in OpenAlex.

  1. SIRT2 deacylase modulators control B cell metabolic reprogramming in EBV infection and mitogenic activation.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Sirtuin 1 Is Required for Optimal Mammarenavirus Multiplication.bioRxiv : the preprint server for biology · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

45 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Emre Koyuncu
Hanna G BudayevaDepartment of Molecular Biology, Princeton University, Princeton, New Jersey, USA.
Yana V MitevaDepartment of Molecular Biology, Princeton University, Princeton, New Jersey, USA.
Dante P RicciDepartment of Molecular Biology, Princeton University, Princeton, New Jersey, USA.
Thomas J SilhavyDepartment of Molecular Biology, Princeton University, Princeton, New Jersey, USA.
Thomas ShenkDepartment of Molecular Biology, Princeton University, Princeton, New Jersey, USA.
Ileana M CristeaDepartment of Molecular Biology, Princeton University, Princeton, New Jersey, USA icristea@princeton.edu.
Princeton University · USForge Life Science (United States) · US

Funding

GENETIC ANALYSIS OF PROTEIN EXPORTR01GM034821 · NIGMS · PRINCETON UNIVERSITY · PI SILHAVY, THOMAS J. · 1985 to 2015
$4.7M
Proteomic Tools to Uncover the Role of Chromatin Remodeling in HIV-1 InfectionDP1DA026192 · NIDA · PRINCETON UNIVERSITY · PI CRISTEA, ILEANA M. · 2008 to 2012
$3.9M
Mechanisms and consequences of metabolic manipulation by human cytomegalovirusR01AI097382 · NIAID · PRINCETON UNIVERSITY · PI RABINOWITZ, JOSHUA D, SHENK, THOMAS E · 2012 to 2015
$2.2M
Human cytomegalovirus latency in cultured monocytesR01AI087672 · NIAID · PRINCETON UNIVERSITY · PI SHENK, THOMAS E · 2010 to 2014
$1.8M
Host Factors Required for Dengue and Yellow Fever Virus AmplificationR33AI102187 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI THOMPSON, SUNNIE R · 2014 to 2015
$786k
Host Factors Required for Dengue and Yellow Fever Virus AmplificationR21AI102187 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CRISTEA, ILEANA M., THOMPSON, SUNNIE R · 2012 to 2013
$414k
NIAID NIH HHS AI87672NIAID NIH HHS AI97382NIAID NIH HHS R01 AI087672NIAID NIH HHS R01 AI097382NIAID NIH HHS R21 AI102187NIAID NIH HHS R21AI102187NIAID NIH HHS R33 AI102187NIDA NIH HHS DP1 DA026192NIDA NIH HHS DP1DA026192NIGMS NIH HHS R01 GM034821
6 · The paper itself

Abstract

unlabelledThe seven human sirtuins are a family of ubiquitously expressed and evolutionarily conserved NAD(+)-dependent deacylases/mono-ADP ribosyltransferases that regulate numerous cellular and organismal functions, including metabolism, cell cycle, and longevity. Here, we report the discovery that all seven sirtuins have broad-range antiviral properties. We demonstrate that small interfering RNA (siRNA)-mediated knockdown of individual sirtuins and drug-mediated inhibition of sirtuin enzymatic activity increase the production of virus progeny in infected human cells. This impact on virus growth is observed for both DNA and RNA viruses. Importantly, sirtuin-activating drugs inhibit the replication of diverse viruses, as we demonstrate for human cytomegalovirus, a slowly replicating DNA virus, and influenza A (H1N1) virus, an RNA virus that multiplies rapidly. Furthermore, sirtuin defense functions are evolutionarily conserved, since CobB, the sirtuin homologue in Escherichia coli, protects against bacteriophages. Altogether, our findings establish sirtuins as broad-spectrum and evolutionarily conserved components of the immune defense system, providing a framework for elucidating a new set of host cell defense mechanisms and developing sirtuin modulators with antiviral activity. IMPORTANCE: We live in a sea of viruses, some of which are human pathogens. These pathogenic viruses exhibit numerous differences: DNA or RNA genomes, enveloped or naked virions, nuclear or cytoplasmic replication, diverse disease symptoms, etc. Most antiviral drugs target specific viral proteins. Consequently, they often work for only one virus, and their efficacy can be compromised by the rapid evolution of resistant variants. There is a need for the identification of host proteins with broad-spectrum antiviral functions, which provide effective targets for therapeutic treatments that limit the evolution of viral resistance. Here, we report that sirtuins present such an opportunity for the development of broad-spectrum antiviral treatments, since our findings highlight these enzymes as ancient defense factors that protect against a variety of viral pathogens.

Indexed as

Virus ReplicationAntiviral AgentsCells, CulturedColiphagesCytomegalovirusEnzyme InhibitorsGene Knockdown TechniquesHost-Pathogen InteractionsHumansInfluenza A Virus, H1N1 SubtypeSirtuinsAntiviral AgentsEnzyme InhibitorsSirtuins

Identifiers

PMID25516616
PMCPMC4271551
OpenAlexW2130879922

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.